ARO-RAGE

Phase 2Small molecule

Arrowhead Pharmaceuticals

ARO-RAGE is one of 69 small molecule programs targeting Lung Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung DiseaseActive, not recruiting

AsthmaActive, not recruiting

Lung DiseasePhase 1/Phase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

Singulair

AstraZeneca

Preclinical

17 4

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 5

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 6

Asmanex

Novartis

Preclinical

5 7

Celexa

AbbVie

Preclinical

1 8

Arcoxia

Aciphex

2 10

ARO-RAGE

Arrowhead Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Asthma

NCT07241546

Clinical

Trials by Indication[1]

Lung Disease1 trial

Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease

Completed· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 1/2·NCT05276570·127 enrolled

Age1 trial

Study of ARO-RAGE in Healthy Subjects

Completed· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 1·NCT05533294·43 enrolled

Asthma1 trial

A Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-induced Mild Asthma

Recruiting· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 2·NCT07241546·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ARO-RAGE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARO-RAGE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARO-RAGE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arrowhead Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Arrowhead Pharmaceuticals

ARO-RAGE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Lung Disease1 trial

Age1 trial

Asthma1 trial

References

Drug Info

Quick Facts

Related News